Advertisement

Topics

Some Respond to Nivolumab After Melanoma Progression (CME/CE)

07:00 EDT 1 Jul 2017 | MedPageToday

(MedPage Today) -- Tumors shrank in 28% of those who stayed on drug after disease progression

Original Article: Some Respond to Nivolumab After Melanoma Progression (CME/CE)

NEXT ARTICLE

More From BioPortfolio on "Some Respond to Nivolumab After Melanoma Progression (CME/CE)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...